Explore the latest content from Journal of Drug Assessment…
#ReadMyResearch campaign. Ever wondered how popular an article is with media outlets or on social media? We are showcasing papers from our Medicine & Health Science journals with high Altmetric scores and impressive Facebook & Twitter downloads. Explore the articles for free today.
Publish your research open access for less. For a limited time only, Journal of Drug Assessment is offering an exclusive discount on the Article Publishing Charge (APC). All submissions made before January 1, 2015 will be eligible for a 30% APC discount. Submit your paper today.
Author Services: new look, new information just for you. Thinking about publishing your research in an academic journal but not sure how to choose where to publish, how to write your article, or what to expect from peer review or during production? To help you navigate through getting published, we’ve re-launched our Author Services website, with lots of new resources. From choosing a journal to how to measure the impact of your work, we guide you through the journal publishing process from initial idea to post-publication, plus every step in between.
Why not explore the fascinating papers within the latest issue from JDA?
- Journal of Drug Assessment
Are you up to date with what everyone's been reading? Peruse the most popular articles from JDA today.
Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium
- Paul Colthorpe, Thomas Voshaar, Thomas Kieckbusch, Erika Cuoghi, Juergen Jauernig
- Draupadi B. Talreja
- Renli Teng, Juan Maya
- Eugene R. Viscusi, James P. Rathmell, Alessandro Fichera, Sander R. Binderow, Robert J. Israel, Frank L. Galasso, Darryl Penenberg, Tong J. Gan
Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers
- C. Gadiko, S. K. Tippabhotla, S. Thota, M. Nakkawar, R. Cheerla, M.R. Betha, V. Vobalaboina
Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis
- Stanley Cohan, Chiayi Chen, Elizabeth Baraban, Tamela Stuchiner, Lois Grote, Monica Rodriguez